Results 81 to 90 of about 750,830 (294)
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism
Molecular Oncology, EarlyView.This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu +13 morewiley +1 more sourceBiotechnological approaches to increase biomass production in trees [PDF]
, 2018 Nutrient use efficiency is one of the factors influencing growth and therefore of high importance for biomass production in trees. Poplar is a model tree widely used for molecular and functional studies and the characterization of transgenic poplars ...Canovas-Ramos, Francisco Miguel, Pascual, Mª Belén, Rueda-López, Marina, Ávila, Concepción +3 morecore The glutaminase-dependent acid resistance system. Qualitative and quantitative assays and analysis of its distribution in enteric bacteria [PDF]
, 2018 Neutralophilic bacteria have developed several strategies to overcome the deleterious effects of acid stress. In particular, the amino acid-dependent systems are widespread, with their activities overlapping, covering a rather large pH range, from 6 to DE BIASE, Daniela, D’Alonzo, Chiara, Freddi, Luca, Occhialini, Alessandra, Pennacchietti, Eugenia +4 morecore +13 more sourcesThe Human SLC1A5 Neutral Amino Acid Transporter Catalyzes a pH-Dependent Glutamate/Glutamine Antiport, as Well
Frontiers in Cell and Developmental Biology, 2020 ASCT2 is a neutral amino acid transporter, which catalyzes a sodium-dependent obligatory antiport among glutamine and other neutral amino acids. The human ASCT2 over-expressed in Pichia pastoris and reconstituted in proteoliposomes has been employed for ...Mariafrancesca Scalise, Tiziano Mazza, Gilda Pappacoda, Lorena Pochini, Jessica Cosco, Filomena Rovella, Cesare Indiveri, Cesare Indiveri +7 moredoaj +1 more sourceIn vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma
Molecular Oncology, EarlyView.Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni +14 morewiley +1 more sourceIn-vivo modification of Azotobacter-chroococcum glutamine-synthetase [PDF]
, 1994 against glutamine synthetase of the unicellular cyanobacterium
Synechocystis sp. strain PCC 6803 immunoreacted with glutamine
synthetase from the N2-fixing heterotrophic bacterium
Azotobacter chroococcum. In Western-blotting experiments this
antibody Aneque Guerrero, Antonio, Cejudo Fernández, Francisco Javier, Muñoz Centeno, María de la Cruz +2 morecore Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine
Molecular Oncology, EarlyView.The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge +18 morewiley +1 more sourceMetabolism within the tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target [PDF]
, 2018 Since reprogramming energy metabolism is considered a new hallmark of cancer, tumor metabolism is again in the spotlight of cancer research. Many studies have been carried out and many possible therapies have been developed in the last years.Abdel-Aziz, Ahmadzadeh, Al-Zhoughbi, Albina, Alkan, Allard, Allen, Altman, Alves-Filho, Amelio, Araújo, Argilés, Arora, Arts, Aslanian, Astaldi, Attieh, Augsten, Auvinen, Babbar, Baker, Balasubramanian, Baltazar, Bauer, Bello-Fernandez, Beloribi-Djefaflia, Berchner-Pfannschmidt, Berge, Berrone, Birendra, Bloch-Frankenthal, Bock, Bock, Bonuccelli, Boros, Boudreau, Boukalova, Britten, Brooks, Broome, Bueno, Buqué, Burnet, Cadamuro, Cahlin, Cantelmo, Cao, Carito, Carmeliet, Carmeliet, Caro, Carrascosa, Casazza, Caspani, Catane, Cavalcante, Chakravarty, Chakravarty, Chakravarty, Chang, Chang, Chang, Chappell, Chaudhary, Chen, Chen, Chen, Chiarini, Chittezhath, Choi, Choi, Clark, Clem, Clem, Cohen, Colegio, Collins, Commisso, Covarrubias, Covarrubias, Dang, Dang, Das, Dasgupta, Daurkin, DeBerardinis, DeBerardinis, Delgoffe, Delgoffe, Dell’ Antone, Desai, DiNapoli, Dirat, Dobrina, Doherty, Dong, Draoui, Dufour, Eason, Eelen, El Sayed, Elia, Elwood, Eminel, Fallarino, Farabegoli, Farber, Feun, Fields, Figueras, Filipp, Fischer, Flaig, Flint, Floor, Floridi, Folkman, Folkman, Franklin, Gacche, Ganeshan, Garber, García-Caballero, García-Faroldi, García-Faroldi, Gatenby, Gazi, Geiger, Gentric, Gerner, Gershtein, Ghashghaeinia, Gonen, Goveia, Granchi, Grieninger, Grivennikov, Gross, Gunnink, Guo, Guo, Guppy, Guth, Halestrap, Han, Hanahan, Hanahan, Hanai, Harjes, Harjes, Haskell, Hatzivassiliou, Hayakawa, Hessini, Hitosugi, Ho, Ho, Hoff, Holm, Hosono, Huang, Hubler, Hui, Häusler, Hée, Ignatenko, Ioannesyants, Ip, Jiménez-Valerio, Jiménez-Valerio, Jochems, Johansen, Jones, Kabat, Kafkewitz, Kamphorst, Kamphorst, Kamphorst, Kannan, Karpel-Massler, Katt, Kawasaki, Kelly, Kim, Klimp, Ko, Koliaraki, Kouidhi, Koukourakis, Kridel, Krishna, Kroemer, Krützfeldt, Kubatka, Kucharzewska, la Cueva, Labow, Laing, Lampropoulou, Le, Lechowski, Lee, Lee, Leek, Leighton, Leopold, LePage, Lerma Barbaro, Li, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Coelho, Lu, Lucca, Lukey, Lunt, Luo, López-Lázaro, Löb, Ma, Madaan, Maity, Marchiq, Martinez-Outschoorn, Martinez-Outschoorn, Maráz, Mashima, Masri, Matusewicz, McCann, McKee, McLaughlin, Medina, Medina, Merchan, Meyer, Mider, Missiaen, Mitra, Mockler, Moreno-Sánchez, Morrison, Mu, Murray-Stewart, Márquez, Márquez, Nacev, Nancolas, Newsholme, Nieman, Nisoli, Noman, Norrby, Noy, Nurjhan, Nyberg, Ocaña, Ohmura, Oka, Opitz, Orimo, Pallangyo, Palm, Panda, Papandreou, Parra-Bonilla, Parry, Pascual, Pasquier, Patsoukis, Pavlides, Pavlova, Pelicano, Pellerin, Pennisi, Penny, Peters, Pisarsky, Pizer, Polanski, Polet, Pollard, Polyak, Possemato, Potente, Potente, Prager, Prager, Pushkina, Pérez-Escuredo, Quatromoni, Quesada, Quesada, Rabold, Ramjiawan, Rashid, Rattigan, Reihill, Reitzer, Ribatti, Ribatti, Ribeiro, Richard, Rider, Roberts, Rodríguez-González, Rodríguez-Prados, Rohle, Romero, Romero-García, Roy, Roy, Ruan, Ruiz-Pérez, Russell, Ryu, Saez, Salimian Rizi, Salimian Rizi, Samal, Samudio, Santos, Sanuphan, Sasaki, Saulnier Sholler, Scherz-Shouval, Schoors, Schulze, Segura, Sekar, Selak, Seltzer, Serafini, Shapot, Shapot, Shapot, Sharkia, Shime, Shin, Shurbaji, Sieber, Siu, Skelton, Song, Sonveaux, Sonveaux, Souba, Sousa, Spahr, Spinelli, Spolarics, Stacpoole, Stern, Stuart, Stumvoll, Su, Sukumar, Sánchez-López, Tachibana, Takigawa, Talekar, Tanese, Tang, Tannahill, Tebbe, Thomas, Thomas, Thornburg, Tisdale, Torosian, Torres, Trudeau, Ullah, Uray, Urdiales, Vander Heiden, Vander Heiden, Varricchi, Vasudevan, Velaei, Vera, Vornovitskaya, Végran, Wagner, Wakil, Wang, Wang, Wang, Wang, Warburg, Warburg, Wen, Whitaker-Menezes, Williams-Ashman, Wilson, Wood, Woodward, Woster, Wu, Wu, Xie, Yamanishi, Yang, Yang, Yau, Yen, Yoshida, Yoshizaki, Yu, Yuan, Yuan, Yuan, Yun, Zabala-Letona, Zahalka, Zhan, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zheng, Zhou, Zhu, Ziegler +431 morecore +2 more sourcesA Metabolomic Approach to Unexplained Syncope
BiomedicinesBackground: This study aims to identify a metabolomic signature that facilitates the classification of syncope and the categorization of the unexplained syncope (US) to aid in its management.Susanna Longo, Ilaria Cicalini, Damiana Pieragostino, Vincenzo De Laurenzi, Jacopo M. Legramante, Rossella Menghini, Stefano Rizza, Massimo Federici +7 moredoaj +1 more sourcePredictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman +17 morewiley +1 more source
